Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. InvaGen Pharmaceuticals, Inc. (D. Del. 2019)

Boehringer Ingelheim Pharmaceuticals Inc. v. InvaGen Pharmaceuticals, Inc. (D. Del. 2019)

Docket		Date Filed	2019-08-09
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	10,258,637
Link to Docket	External link to docket

Details for Boehringer Ingelheim Pharmaceuticals Inc. v. InvaGen Pharmaceuticals, Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-08-09				External link to document

Boehringer Ingelheim v. InvaGen Pharmaceuticals, 1:19-cv-01496: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Boehringer Ingelheim Pharmaceuticals sued InvaGen Pharmaceuticals in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act after InvaGen filed an ANDA seeking approval for a generic version of Tradjenta, whose active ingredient is linagliptin. The action was an ANDA-based patent infringement case under 35 U.S.C. § 271(e)(2). The dispute did not produce a reported merits decision establishing invalidity or noninfringement. The case was resolved through a negotiated disposition and ultimately dismissed.

What drug was involved in Boehringer Ingelheim v. InvaGen?

The case concerned linagliptin, the active pharmaceutical ingredient in Tradjenta tablets.

Item	Information
Brand product	Tradjenta
Active ingredient	Linagliptin
Therapeutic class	DPP-4 inhibitor
Reference sponsor	Boehringer Ingelheim Pharmaceuticals, Inc.
Regulatory pathway	Abbreviated New Drug Application
Defendant	InvaGen Pharmaceuticals, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:19-cv-01496
Statutory basis	35 U.S.C. § 271(e)(2)
Judicial outcome	Disposition without a reported merits judgment

Tradjenta is approved for glycemic control in adults with Type 2 diabetes. Linagliptin inhibits dipeptidyl peptidase-4, increasing incretin activity and improving glucose-dependent insulin secretion. The product is administered as a once-daily oral tablet.[1]

What patents protected Tradjenta and linagliptin?

The principal patent estate for Tradjenta included compound, pharmaceutical-composition, and method-of-use protection. The most important early patent was U.S. Patent No. 7,407,955, which covered linagliptin-related xanthine compounds and was assigned to Boehringer-affiliated entities.[2]

The relevant protection categories were:

Patent category	Subject matter	Commercial significance
Compound patents	Linagliptin and related xanthine derivatives	Core active-ingredient protection
Composition patents	Pharmaceutical formulations containing linagliptin	Potential restrictions on tablet composition
Method-of-use patents	Treatment of Type 2 diabetes with DPP-4 inhibition	May delay or narrow generic labeling
Solid-form or manufacturing patents	Crystalline forms, processes, or intermediates	Can create technical barriers but may not block a basic ANDA

The exact patents asserted against InvaGen must be determined from the complaint, amended pleadings, and the applicable Orange Book entries for the asserted NDA. Public summaries of the case should not be treated as proof that every Tradjenta-related patent was asserted in this particular action.

What was the procedural history of the case?

The case followed the standard Hatch-Waxman sequence:

1. InvaGen filed an ANDA for a generic linagliptin product.
2. InvaGen served a Paragraph IV certification challenging one or more Orange Book-listed patents.
3. Boehringer filed the Delaware action within the statutory 45-day period.
4. The filing triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).
5. The parties litigated claim, validity, and infringement issues but did not obtain a reported final judgment after trial.
6. The court entered a dismissal or stipulated termination consistent with resolution of the dispute.

The complaint itself constituted an artificial act of infringement under § 271(e)(2). That provision permits the brand sponsor to litigate patent issues before the generic product reaches the market.

Was there a Paragraph IV challenge?

Yes. The case was an ANDA patent action, which means InvaGen’s filing included a certification that at least one listed patent was invalid, unenforceable, or would not be infringed by the proposed generic product. A Paragraph IV certification is not an admission of infringement. It is the statutory mechanism used by an ANDA applicant to seek FDA approval before expiration of listed patents.

The Paragraph IV filing created two commercial effects:

• It gave Boehringer a basis to sue in federal court.
• It imposed the 30-month FDA approval stay, unless the stay was shortened or terminated by a court order or other statutory event.

The litigation did not result in a published decision finding that the challenged Tradjenta patents were valid and infringed. It also did not establish that the patents were invalid or unenforceable.

When did Tradjenta lose exclusivity?

Tradjenta’s exclusivity ended in stages rather than on a single date.

Regulatory exclusivity

FDA approval of Tradjenta occurred in 2011. New chemical entity exclusivity generally lasts four years, while five-year NCE exclusivity applies to a drug containing a new active moiety. Because the relevant exclusivity period had expired before InvaGen’s 2019 litigation, the dispute centered on patent rights rather than FDA exclusivity.

Patent exclusivity

The core linagliptin patent estate began expiring in the early 2020s. The practical generic-entry date depended on:

• The specific patents listed for the ANDA reference product.
• Any pediatric exclusivity extension.
• The terms of the Boehringer-InvaGen settlement.
• Other patents covering dosage forms, combinations, or methods of treatment.
• FDA approval timing and any first-applicant exclusivity.

A patent expiration date alone does not prove that a generic applicant could launch. A settlement may provide an earlier authorized launch date, while unexpired method or formulation patents may create narrower litigation risk.

What was the litigation outcome?

The litigation ended without a reported substantive opinion on the asserted patent claims. The public procedural record supports the following conclusions:

• InvaGen did not obtain a published ruling invalidating the asserted patents.
• Boehringer did not obtain a published trial judgment establishing infringement.
• The case did not create a binding claim-construction or validity precedent for later Tradjenta litigation.
• The commercial terms of any settlement were not fully disclosed in the public court docket.

A stipulated dismissal in a Hatch-Waxman case generally indicates that the parties reached a private resolution or that the action was otherwise terminated. It does not identify the agreed generic launch date unless the settlement agreement or a related filing makes that term public.

Did the settlement permit an early generic launch?

The public disposition does not establish a definitive generic launch date for InvaGen. Hatch-Waxman settlements commonly contain one or more of the following provisions:

• A permitted launch date before patent expiration.
• A license to market after a specified date.
• A covenant not to sue for particular products.
• Restrictions tied to patent validity or infringement.
• An authorized-generic arrangement.
• A no-challenge clause or other commercial conditions.

The Federal Trade Commission and Department of Justice review pharmaceutical patent settlements for potential anticompetitive effects under the Federal Trade Commission Act and the Medicare Prescription Drug, Improvement, and Modernization Act reporting framework. A settlement report can provide more detail than the district-court docket, but absence of a public term does not establish that the settlement lacked an early-entry provision.[3]

What was the FDA and Orange Book status?

The FDA’s Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with the reference product. For Tradjenta, the relevant regulatory analysis requires separating:

• Patents listed against the linagliptin tablet NDA.
• Patents listed against combination products such as linagliptin and metformin.
• Expired patents.
• Unexpired formulation or method-of-use patents.
• Patents removed or delisted after challenge.

An Orange Book listing creates the statutory framework for Paragraph IV litigation, but it does not establish patent validity. A listed patent may be challenged on written-description, enablement, obviousness, anticipation, patentable subject matter, or infringement grounds.

The FDA’s approval of a later ANDA would also depend on the applicant’s certification to each listed patent. A generic applicant may use a Paragraph III certification, Paragraph IV certification, or a section viii statement that omits a patented method of use from the labeling.

How strong was Boehringer’s patent estate?

Boehringer’s estate had moderate-to-strong historical protection for the active ingredient because compound protection is usually more difficult to design around than a formulation or method-of-use claim. The strength of the estate declined as the core compound patent approached expiration.

Core compound protection

Compound patents can block substantially all generic products containing the claimed molecule. They therefore present the largest commercial risk to an ANDA applicant. Their durability depends on claim scope, priority support, enablement, and whether the claimed genus adequately covers the commercial compound.

Formulation protection

Formulation patents generally provide narrower protection. A generic applicant may avoid infringement through differences in excipients, tablet structure, dosage form, or manufacturing process. Formulation patents can still delay entry when the reference product’s formulation is difficult to replicate without using the claimed features.

Method-of-use protection

Method patents may be less effective against a full-label generic because a generic applicant can pursue a section viii carve-out for the patented indication. Their value is greater when the protected method is central to the approved labeling or when the patent claims a broad treatment regimen that is difficult to omit.

What generic entry risks did InvaGen face?

InvaGen faced four principal risks.

Approval delay

The lawsuit triggered the statutory 30-month stay, delaying FDA approval unless the stay was terminated earlier.

Patent liability

If Boehringer prevailed, the court could have enjoined commercial approval or launch until the relevant patents expired.

Labeling restrictions

A section viii carve-out could have reduced the commercial scope of InvaGen’s label, particularly if an unexpired method-of-use patent covered a specific patient population or treatment combination.

Settlement constraints

A settlement could have allowed entry before patent expiration but imposed a fixed launch date, product restrictions, or other contractual limitations. The lack of public settlement terms prevents a definitive assessment of InvaGen’s negotiated launch rights.

Which companies challenged Tradjenta patents?

Boehringer faced broader generic pressure from multiple ANDA applicants as the linagliptin patent estate matured. The competitive field included major generic manufacturers and smaller applicants that could challenge the compound, formulation, or use patents through Paragraph IV certifications.

The InvaGen case should be viewed as one proceeding within that wider erosion of Tradjenta exclusivity. A dismissal in one case did not resolve the validity of the patent estate against other applicants. Each ANDA applicant could raise distinct claim-construction, invalidity, infringement, or labeling arguments.

What was the commercial exposure?

Tradjenta was a significant Boehringer product, but its commercial exposure was lower than that of the largest diabetes brands such as Januvia, Jardiance, or Farxiga. Generic entry threatened:

• Net sales from linagliptin tablets.
• Hospital and managed-care formulary positioning.
• Combination-product prescribing.
• Price protection for the Tradjenta franchise.
• Potential switching to other DPP-4 inhibitors or low-cost generic alternatives.

The economic impact of InvaGen’s case depended on whether InvaGen was permitted to launch before basic patent expiry, whether it received first-filer exclusivity, and whether competing ANDA applicants entered at the same time.

How does this case compare with other Hatch-Waxman cases?

Issue	Boehringer v. InvaGen	Typical ANDA patent case
Product	Tradjenta linagliptin tablets	Small-molecule prescription drug
Legal trigger	Paragraph IV certification	Paragraph IV certification
Court	District of Delaware	Delaware, New Jersey, or other patent venue
Primary dispute	Listed linagliptin patent rights	Validity, infringement, or enforceability
Regulatory consequence	30-month stay	30-month stay
Public merits ruling	None reported	May include claim construction or trial judgment
Commercial result	Private resolution and dismissal	Settlement, judgment, or dismissal

Unlike biologic litigation under the BPCIA, this case did not involve biosimilar interchangeability, the patent dance, or a biologic-license application. The relevant competitive threat was conventional generic entry through the ANDA pathway.

Key Takeaways

• Boehringer sued InvaGen in Delaware after an ANDA and Paragraph IV challenge involving generic linagliptin.
• The reference product was Tradjenta.
• The case was governed by Hatch-Waxman’s artificial-infringement and 30-month-stay provisions.
• The action ended without a reported merits decision on patent validity or infringement.
• The public record does not establish the complete commercial terms or a definitive InvaGen launch date.
• Boehringer’s strongest protection came from the core linagliptin compound estate; formulation and method patents were narrower and more vulnerable to design-around or label carve-outs.
• The case did not eliminate generic-entry risk for other ANDA applicants.
• The dispute was a small-molecule generic case, not a biosimilar proceeding.

FAQs

Did InvaGen receive FDA approval for generic Tradjenta?

The litigation record alone does not establish the timing or commercial status of any InvaGen ANDA approval. FDA approval must be confirmed through the FDA’s ANDA and Orange Book records.

Was U.S. Patent No. 7,407,955 invalidated in this case?

No reported decision in this action establishes invalidity of that patent. The case ended without a published merits judgment.

Could InvaGen launch before all Tradjenta patents expired?

Only if permitted by a settlement, an FDA determination, or a successful Paragraph IV judgment. A dismissal alone does not disclose an authorized launch date.

Did this case involve Jardiance or Synjardy?

No. The case is associated with the linagliptin product Tradjenta, not empagliflozin products such as Jardiance or Synjardy.

Are Tradjenta method-of-use patents still a major generic barrier?

Method-of-use patents can restrict labeling or treatment claims, but their practical blocking effect depends on the remaining patent term, the possibility of a section viii carve-out, and whether the patented use is commercially necessary.

References

1. U.S. Food and Drug Administration. (2011). Trad­jenta (linagliptin) prescribing information.
2. U.S. Patent and Trademark Office. (2008). U.S. Patent No. 7,407,955, xanthine derivatives.
3. Federal Trade Commission. (2023). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
4. U.S. District Court for the District of Delaware. (2019). Boehringer Ingelheim Pharmaceuticals, Inc. v. InvaGen Pharmaceuticals, Inc., No. 1:19-cv-01496.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.